NCT04402268View on ClinicalTrials.gov

Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy

CompletedOBSERVATIONAL
Enrollment

252

Participants

Timeline

Start Date

October 1, 2014

Primary Completion Date

September 1, 2018

Study Completion Date

February 28, 2019

Conditions
Hypertrophic Cardiomyopathy
Interventions
DEVICE

Cardioverter-defibrillator

We analyzed how many HCM patients reached an end-point of sudden cardiac death defined as adequate intervention of cardioverter-defibrillator or sudden cardiac arrest.

Trial Locations (1)

61-848

Poznan Univeristy of Medical Sciences, Poznan

All Listed Sponsors
lead

Poznan University of Medical Sciences

OTHER

NCT04402268 - Efficacy of Risk Assessment for Sudden Cardiac Death in Patients With Hypertrophic Cardiomyopathy | Biotech Hunter | Biotech Hunter